Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $13.9552W HIGH $72.51
Volume
1.57 M
Value Traded
58.40 M
Short % Float
13.38%
-7.36%Week
+24.34%1 Month
+118.19%3 Month
+287.57%6 Month
-70.77%5 Year
+127.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.22 B
EPS (TTM)
2.15
P/E Ratio
28.99
Ent. Value
2.84 B
Total Shares
51.74 M
Float Shares
47.08 M
Insiders
9.01%
Institutions
99.39%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CDNA Catalyst Timeline
Dated clinical, regulatory and corporate events for CareDx, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for CareDx, Inc.
3Total events
0Upcoming
2Tier-1 (high impact)
2026 to 2026Coverage
Past FDA Catalysts and PDUFA Decisions
How CDNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
CareDx, Inc. is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CDNA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| AlloHeme | acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) | 2026-02-12 | sensitivity: 85%; specificity: 92%; negative predictive value: 95%; positive predictive value: 79%; area under curve: 0.89; median detection lead time: 41 days; relapse risk increase: 12-fold higherRead More | CareDx Announces Clinical Validation Results for AlloHeme™, the First AI‑Powered NGS Surveillance Solution for AML and MDS Post‑Cell TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PETER MAAGDirector | Sell | 9,122 | $46.38 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CDNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Palo Alto Investors LP | 2.1 % (50 %) | 15.16 M | 531.87 K |
CDNA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CDNA ranks across every disease it competes in
Competitive Position is a premium feature
See how CDNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCDNA News
CDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. has announced the award of inducement grants to 35 new employees as part of their employment acceptance. A total of 97,090 shares of common stock in the form of restricted stock units (RSUs) have been allocated, with the majority set to vest over time. This move indicates the company's commitment to growth and employee engagement.
Read more →CDNA▲ +14.7%on this news· ran to +26% by day 1
CareDx Announces Second Quarter 2026 Financial Results
CareDx, Inc. reported its financial results for the second quarter of 2026, highlighting a significant revenue increase of 52% compared to the previous year. The company's Testing Services revenue also saw a notable rise of 61%, with approximately 58,000 tests performed, marking a 17% increase in volume. These results reflect strong growth in the company's precision medicine diagnostics business.
Read more →CDNA▲ +35.6%on this news
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026
CareDx, Inc. will announce its financial results for the second quarter of 2026 on July 30, 2026, after market close. The company, known for its work in precision medicine diagnostics, will also host a conference call and webcast at 1:30 p.m. PT. This event will provide stakeholders with insights into the company's performance.
Read more →CDNA▲ +35.6%on this newsshared move
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination
CareDx, Inc. has finalized the Medicare Local Coverage Determination for molecular testing related to solid organ allograft rejection. This policy confirms coverage for their transplant surveillance products, including AlloSure® Kidney, and extends to heart and lung transplants. This development is significant for enhancing patient monitoring in organ transplant recipients.
Read more →CDNACareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology
CareDx has successfully completed the acquisition of Naveris, a strategic move aimed at enhancing its position in the specialty oncology market. This acquisition is expected to drive growth and expand CareDx's offerings in a high-demand area. The integration of Naveris will further solidify CareDx's leadership in oncology.
Read more →CDNAEurobio Scientific finalizes the acquisition of CareDX’s transplant Lab Product division
Eurobio Scientific has finalized the acquisition of CareDx's Lab Products division, enhancing its capabilities in in-vitro diagnostics for transplantation. This strategic move aims to create a leading provider of genomic typing and transplantation diagnostics. The integration will expand product offerings and improve operational efficiencies across key markets.
Read more →CDNACareDx Announces Completion of Sale of Lab Products Business to Eurobio Scientific
CareDx has announced the completion of the sale of its lab products business to Eurobio Scientific. This strategic move is part of CareDx's ongoing efforts to streamline operations and focus on its core competencies. The transaction is expected to enhance both companies' market positions in the diagnostics sector.
Read more →CDNA▲ +11.5%on this news
CareDx Precision Medicine Diagnostics Showcased in Over 30 Abstracts and 9 Oral Presentations at the 2026 American Transplant Congress
CareDx showcased its precision medicine diagnostics at the 2026 American Transplant Congress, presenting over 30 abstracts and 9 oral presentations. This event highlights the company's commitment to advancing transplant medicine through innovative diagnostic solutions. The presentations are expected to contribute valuable insights into the field.
Read more →CDNACareDx Announces Second KOAR Analysis Published in the Journal of the American Society of Nephrology
CareDx has announced the publication of its second KOAR analysis in the Journal of the American Society of Nephrology. This publication highlights the ongoing research and findings related to kidney transplant management. Details about the analysis and its implications for patient care were not disclosed in the announcement.
Read more →CDNACareDx to Participate in Upcoming June 2026 Investor Conferences
CareDx, Inc. (CDNA) has announced its participation in investor conferences scheduled for June 2026. The company will host a fireside chat on June 8, 2026, at 1:20 PM ET. Webcasts of the presentations will be accessible via their investor relations website, highlighting their commitment to transparency and investor engagement.
Read more →CDNACareDx to Participate in Upcoming Investor Conferences
CareDx has announced its participation in upcoming investor conferences. The details regarding the specific conferences and the nature of their participation were not disclosed in the article. This move is likely aimed at enhancing investor relations and visibility in the market.
Read more →CDNACareDx Announces Dismissal of 2021 Qui Tam Suit
CareDx has announced the dismissal of a qui tam lawsuit filed in 2021. This legal victory may positively impact the company's reputation and investor confidence. The dismissal signifies a resolution to the legal challenges faced by CareDx, allowing the company to focus on its core operations.
Read more →CDNACareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
CareDx, Inc. has announced the award of inducement grants to 23 new employees, totaling 63,856 restricted stock units (RSUs). These grants are part of the company's 2019 and 2025 Inducement Equity Incentive Plans, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, promoting employee retention.
Read more →CDNACareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx has announced a definitive agreement to acquire Naveris, a leader in viral-mediated cancer monitoring. The acquisition, valued at $160 million upfront and additional milestone payments, aims to enhance CareDx's precision medicine services. Naveris's liquid biopsy platform is recognized for its accuracy in detecting HPV-driven cancers. The transaction is expected to close in Q3 2026, pending customary conditions.
Read more →CDNACareDx Announces First Quarter 2026 Financial Results
CareDx, Inc. reported strong financial results for Q1 2026, with revenues reaching $118 million, a 39% increase from the previous year. The company saw significant growth in testing services, which rose by 48%, and achieved a GAAP net income of $3 million, a turnaround from a loss in Q1 2025. CareDx also announced a strategic divestiture of its Lab Products business and launched an AI-driven clinical data platform.
Read more →CDNACareDx Announces Presentation of More Than 50 Abstracts Including 16 Oral Presentations at the International Society for Heart and Lung Transplantation’s 46th Annual Meeting
CareDx, Inc. announced its participation in the ISHLT 2026 Annual Meeting, where it will present more than 50 abstracts, including 16 oral presentations. This event, scheduled for April 22-25 in Toronto, Canada, emphasizes CareDx's commitment to advancing transplant medicine through innovative research and clinical applications.
Read more →CDNACareDx Introduces AlloSeq Nano at EFI 2026, Expanding HLA Typing Portfolio with Long-Read Sequencing
CareDx has introduced AlloSeq Nano at EFI 2026, enhancing its HLA typing portfolio through long-read sequencing technology. This development aims to improve the accuracy and efficiency of HLA typing, which is crucial for organ transplantation. The introduction of this new product reflects CareDx's commitment to advancing transplant diagnostics.
Read more →CDNA▲ +27.6%on this newsshared move
CareDx Announces Agreement to Divest Lab Products Business to EuroBio Scientific for $170 Million and Announces First Quarter Preliminary Financial Results
CareDx has announced a definitive agreement to divest its Lab Products business to EuroBio Scientific for $170 million. This strategic move aims to enhance CareDx's focus on its core precision medicine testing services, which have shown significant revenue growth. The transaction is expected to close by the end of the third quarter of 2026, pending regulatory approval.
Read more →CDNACareDx to Report First Quarter 2026 Financial Results on April 28, 2026
CareDx, Inc. has announced that it will report its financial results for the first quarter of 2026 on April 28, 2026. The report will be released after market close, followed by a webcast and conference call at 1:30 p.m. PT. The company specializes in precision medicine for transplant patients.
Read more →About CareDx, Inc.
Headquarters8000 MARINA BLVD, BRISBANE, CA, 94005
BIOPHARMAWATCH ELITE PLUS
Trade the next CDNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime